Replies to post #2675 on Safeplus International Holdings Ltd. (ACAI)

[sunspotter]

Here's a genuine question I'd like a Biophan-atic to answer:

I've been assured on several occasions by Biophan supporters that even after the payments for a "controling" share in Myotech, and the so far undisclosed payment for the Nanoset IP, there's plenty of the $11 million that Medtronic paid BIPH back at the tail-end of 2007.

That being the case, why don't Biophan use that cash to pay of some, or all, of their so-called "sewer rat" debt?

After all, it seems we are all agreed that the monthly sell-off of the shares granted in lieu of cash to these "sewer rats" is extremely bad for the pps. It also gives the impression of a management that doesn't care about the investments of its ordinary retail sharholders.

Surely Biophan should have two priorities right now.

Firstly to pay off the toxic financiers (and apologise to you guys for doing this to you in the first place).

Secondly to get the Myotech CSS device into human trials under an FDA-approved protocol now.

The Medtronic money should be enough to do both of these things.

So why doesn't BIPH do either?

They talk about the latter but don't do it, and the former is simply unmentioned in their communications.

I find it all very odd.

Can some one please enlighten me? What am I missing?